Background: Basal insulin analogues aim for protracted glycemic control with minimal
adverse effects. Purpose: To assess the comparative efficacy and safety of basal insulin …

Treat‐to‐target trial designs compare investigational insulins with a standard insulin. Treat‐
to‐target trials force‐titrate insulin dosages to achieve a prespecified treatment goal. With …

Background: We set out to study the relationship between different measures of glycemic
variability and the rate of hypoglycemia in patients with type 2 diabetes. Subjects and …

OBJECTIVE This multicenter, open-label, parallel-arm study compared the efficacy and
safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 …

Since its discovery and first clinical use in the 1920s, insulin therapy has revolutionized the
treatment and natural history of both type 1 and type 2 diabetes mellitus. This article …

OBJECTIVE Hypoglycemia causes recurrent morbidity in patients with type 2 diabetes. This
study evaluated if exenatide twice daily (BID) was noninferior to premixed insulin aspart …

Insulin detemir (Levemir®) is a long-acting insulin analogue indicated for use as basal
insulin therapy in patients with type 1 or 2 diabetes mellitus. The protracted action of insulin …

Insulin was discovered by Banting and Best in 1921. Soon afterwards, manufacturing
processes were developed to extract the insulin from porcine and bovine pancreata. From …

We conducted a systematic review of randomized controlled trials that evaluated the
effectiveness of insulin regimens (basal, biphasic, prandial, and basal-bolus) with insulin …

Abstract Aim Evaluate early (0–12 weeks) and later (12–24 weeks) treatment outcomes in
subjects with type 2 diabetes not achieving glycaemic control with oral antidiabetes drugs …